Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Dhruv Chopra, MS, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 5378.

https://doi.org/10.1182/blood-2019-131028

Published: 2019

Journal Articles

Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)

Philippe Moreau, MD, Cyrille Hulin, MD, Sonja Zweegman, MD PhD, Yannan Hu, PhD, Bart Heeg, PhD, Mahmoud Hashim, Carla de Boer, Veronique Vanquickelberghe, Tobias Kampfenkel, MD, Annette Lam, Sarah Cote, Pieter Sonneveld

Blood (2019) 134 (Supplement_1): 4740.

https://doi.org/10.1182/blood-2019-123491

Published: 2019

Journal Articles

Unusual Long Term Remission in Multiple Myeloma Using Conventional Therapy Combined with Danazol

Matthew P Salzberg, MD, Pamela B. Dudkiewicz, DNP, ARNP, Lawrence L. Horstman, BS, Wenche Jy, PhD, Yeon S. Ahn, MD

Blood (2017) 130 (Supplement 1): 5423.

https://doi.org/10.1182/blood.V130.Suppl_1.5423.5423

Published: 2017

Journal Articles

Patterns and Determinants of Cancer-Directed Drug Therapy in Medicare Beneficiaries with Multiple Myeloma

Julia F Slejko, PhD, Dorothy Romanus, RPh, MSc, PhD, Daisuke Goto, PhD, Eberechukwu Onukwugha, PhD, Rahul Khairnar, MS, Brian Seal, RPh, MBA, PhD, Candice Yong, PhD, Jean Yared, MD

Blood (2016) 128 (22): 5926.

https://doi.org/10.1182/blood.V128.22.5926.5926

Published: 2016

Journal Articles

Evaluation of Bone Marrowmmorphology in Addition to JAK2 Allele Burden Is Essential for Assessing Disease Status in Recombinant Interferon Alpha-Treated Polycythemia Vera Patients

Elizabeth Michelle Margolskee, MD MPH, Spencer Krichevsky, Attilio Orazi, MD, Richard T. Silver, MD

Blood (2016) 128 (22): 5471.

https://doi.org/10.1182/blood.V128.22.5471.5471

Published: 2016

Journal Articles

Recombinant Interferon Alpha (rIFN) May Retard Progression Of Early Myelofibrosis By Reducing Splenomegaly and By Decreasing Marrow Fibrosis

Richard T. Silver, Elena Lascu, Eric J. Feldman, MD, Ellen Ritchie, MD, Gail J. Roboz, MD, Maria Teresa De Sancho, MD, MSc, Ruth Bauman, Attilio Orazi, MD

Blood (2013) 122 (21): 4053.

https://doi.org/10.1182/blood.V122.21.4053.4053

Published: 2013

Journal Articles

Complete Response to Thalidomide and Dexamethasone in a Patient with Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathy of Uncertain Significance (MGUS)

Yvonne A Efebera, MD, Elizabeth Blanchard, MD, Andrew J Han, Charles Allam, MD, Nikhil C. Munshi, MD

Blood (2008) 112 (11): 5210.

https://doi.org/10.1182/blood.V112.11.5210.5210

Published: 2008

Journal Articles

Zidovudine Blocks NF-κB activity in Vivo in Adult T-Cell Leukemia

Juan Carlos Ramos, MD, Luis M. Diaz, Michele Manrique, Rosangela Lima, Ngoc L Toomey, Tianli Xia, Lisa Cabral, Toumy Guettouche, Carlos Brites, William J. Harrington, MD

Blood (2008) 112 (11): 2524.

https://doi.org/10.1182/blood.V112.11.2524.2524

Published: 2008

Journal Articles

Thalidomide-Dexamethasone Versus Melphalan-Prednisolone as First Line Treatment in Elderly Patients with Multiple Myeloma: An Interim Analysis.

Heinz Ludwig, MD, Johannes Drach, MD, Elena Tóthová, MD, Heinz Gisslinger, MD, Werner Linkesch, MD, Boris Jaksic, MD, Michael Fridik, MD, Josef Thaler, MD, Alois Lang, MD, Roman Hajek, MD, Niklas Zojer, MD, Richard Greil, MD, Ingrid Kuhn, Axel Hinke, Boris Labar, MD

Blood (2005) 106 (11): 782.

https://doi.org/10.1182/blood.V106.11.782.782

Published: 2005

Journal Articles

Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results.

Blood (2005) 106 (11): 4962.

https://doi.org/10.1182/blood.V106.11.4962.4962

Published: 2005

Journal Articles

Lymhoma of the Oral Cavity. A Rare Entity with Favorable Prognosis. Ten-Year Experience of a Single Hematology Unit.

Marina P. Siakantaris, MD, Tatiana Tzenou, MD, Theodoros P. Vassilakopoulos, MD, Marie-Christine Kyrtsonis, MD, Maria K. Angelopoulou, MD, Maria N. Dimopoulou, MD, Styliani I. Kokoris, MD, Evangelia N. Dimitriadou, MD, Penelope Korkolopoulou, MD, Efstratios Patsouris, MD, Panayiotis Tsaftaridis, MD, Eleni Variamis, MD, George Laskaris, MD, Gerassimos A. Pangalis, MD

Blood (2004) 104 (11): 4595.

https://doi.org/10.1182/blood.V104.11.4595.4595

Published: 2004

Journal Articles

Interferon Alpha-2B (IFN-a) Is an Effective Agent for the Treatment of Primary Cutaneous T- and B-Cell Lymphoma.

Marina P. Siakantaris, MD, Marie-Christine Kyrtsonis, MD, Tatiana Tzenou, MD, Evangelia M. Dimitriadou, MD, Maria N. Dimopoulou, MD, Maria K. Angelopoulou, MD, Styliani I. Kokoris, MD, Theodoros P. Vassilakopoulos, MD, Penelope Korkolopoulou, MD, Antonia Giannakakis, MD, Eleni Plata, MD, Eustratios Patsouris, MD, Andreas Katsambas, MD, Gerassimos A. Pangalis, MD

Blood (2004) 104 (11): 2643.

https://doi.org/10.1182/blood.V104.11.2643.2643

Published: 2004

Journal Articles

Results of a Phase II Trial of Oral Bexarotene Combined with Interferon Alfa-2b for Patients with Cutaneous T-Cell Lymphoma (CTCL).

David J. Straus, M.D., Madeleine Duvic, M.D., Timothy Kuzel, M.D., Steven Horwitz, M.D., Marie-France Demierre, M.D., Patricia Myskowski, M.D., Kathleen Maignan, B.A., Steven Steckel, Pharm.D.

Blood (2004) 104 (11): 2644.

https://doi.org/10.1182/blood.V104.11.2644.2644

Published: 2004

Journal Articles

Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results.

Blood (2004) 104 (11): 1523.

https://doi.org/10.1182/blood.V104.11.1523.1523

Published: 2004

Journal Articles

Genetic Modifiers of Cerebrovascular Large Vessel Stenosis in Sickle Cell Anemia.

M. Catherine Driscoll, MD, Joseph Devaney, PhD, Heather Gordish, PhD, Caterina Minniti, MD, Eric P. Hoffman, PhD

Blood (2004) 104 (11): 1658.

https://doi.org/10.1182/blood.V104.11.1658.1658

Published: 2004

Journal Articles

Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma

Caroline M. P. W. Mandigers, Jules P. P. Meijerink, Ewald J. B. M. Mensink, Evelyn L. R. T. M. Tönnissen, Konnie M. Hebeda, M. José J. T. Bogman, John M. M. Raemaekers

Blood (2001) 98 (4): 940–944.

https://doi.org/10.1182/blood.V98.4.940

Published: 2001

Journal Articles

Truncated mutant B subunit for factor XIII causes its deficiency due to impaired intracellular transportation

Shiori Koseki, Masayoshi Souri, Shinichiro Koga, Mitsunori Yamakawa, Tsutomu Shichishima, Yukio Maruyama, Fumio Yanai, Akitada Ichinose

Blood (2001) 97 (9): 2667–2672.

https://doi.org/10.1182/blood.V97.9.2667

Published: 2001

NARROW

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)

Unusual Long Term Remission in Multiple Myeloma Using Conventional Therapy Combined with Danazol

Patterns and Determinants of Cancer-Directed Drug Therapy in Medicare Beneficiaries with Multiple Myeloma

Evaluation of Bone Marrowmmorphology in Addition to JAK2 Allele Burden Is Essential for Assessing Disease Status in Recombinant Interferon Alpha-Treated Polycythemia Vera Patients

Recombinant Interferon Alpha (rIFN) May Retard Progression Of Early Myelofibrosis By Reducing Splenomegaly and By Decreasing Marrow Fibrosis

Complete Response to Thalidomide and Dexamethasone in a Patient with Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathy of Uncertain Significance (MGUS)

Zidovudine Blocks NF-κB activity in Vivo in Adult T-Cell Leukemia

Thalidomide-Dexamethasone Versus Melphalan-Prednisolone as First Line Treatment in Elderly Patients with Multiple Myeloma: An Interim Analysis.

Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results.

Lymhoma of the Oral Cavity. A Rare Entity with Favorable Prognosis. Ten-Year Experience of a Single Hematology Unit.

Interferon Alpha-2B (IFN-a) Is an Effective Agent for the Treatment of Primary Cutaneous T- and B-Cell Lymphoma.

Results of a Phase II Trial of Oral Bexarotene Combined with Interferon Alfa-2b for Patients with Cutaneous T-Cell Lymphoma (CTCL).

Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results.

Genetic Modifiers of Cerebrovascular Large Vessel Stenosis in Sickle Cell Anemia.

Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma

Truncated mutant B subunit for factor XIII causes its deficiency due to impaired intracellular transportation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only